AIkido Pharma Inc
AIKI
Get informed when a big investor buys or sells
+ FollowMarket Cap$19.53M
Close$
$5.90
65.6% upside
Current Fair Value
65.6% upsideUndervalued by 65.6% based on the discounted cash flow analysis.
Share Statistics
| Market cap | $19.53 Million |
|---|---|
| Enterprise Value | $10.06 Million |
| Dividend Yield | $- (37.31%) |
| Earnings per Share | $-1.57 |
| Beta | 0 |
| Outstanding Shares | 22,754,753 |
Return
| Return on Equity | -317.39% |
|---|---|
| Return on Assets | -120.74% |
| Return on Invested Capital | 200.21% |
Valuation & Multiples
| P/E Ratio | -0.74 |
|---|---|
| PEG | 0.56 |
| Price to Sales | 0.71 |
| Price to Book Ratio | - |
| Enterprise Value to Revenue | 0.08 |
| Enterprise Value to EBIT | 0.12 |
| Enterprise Value to Net Income | -1 |
| Total Debt to Enterprise | 1.55 |
| Debt to Equity | 0.71 |
Revenue Sources
No data
Insider Trades
Institutional Sentiment (Put/Call)
No data available for the latest quarter.
Institutional Ownership
No data available for the latest quarter.
ESG Score
No data
About AIkido Pharma Inc
CEO: Anthony Hayes AIkido Pharma Inc. was initially formed in 1967 and is a biotechnology company with a diverse portfolio of small-molecule anti-cancer therapeutics. The Company's platform consists of patented technology from leading universities and res...